Pamrevlumab Emerging Drug Insight

“Pamrevlumab Market Size, Forecast, and Emerging Insight – 2032” report provides comprehensive insights about pamrevlumab for Progressive Fibrosing Interstitial Lung Diseases (PF-ILD) in the seven major markets. A detailed picture of the pamrevlumab for PF-ILD in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the pamrevlumab for PF-ILD. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the pamrevlumab market forecast analysis for PF-ILD in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in PF-ILD.

Drug Summary

FibroGen is developing pamrevlumab (also known as FG-3019), an intravenously administered, first-in-class, fully-humanized monoclonal antibody that inhibits the activity of connective tissue growth factor activity, or CTGF, a critical mediator in the progression of fibrosis and related serious diseases.

After successfully completing the Phase II clinical study, FibroGen is advancing pamrevlumab in a Phase III clinical development for the treatment of IPF. The company is conducting two randomized, double-blind, placebo-controlled, Phase III studies of pamrevlumab in IPF. Each study has a primary efficacy endpoint (for the US) of change from baseline in forced vital capacity (FVC). For Europe, these trials have a primary efficacy endpoint of disease progression (defined by a decline in FVC percent predicted of greater than or equal to 10% or death). Secondary endpoints will include clinical outcomes of disease progression, acute IPF exacerbations, patient reported outcomes, and quantitative changes in lung fibrosis volume from baseline. Enrollment of ZEPHYRUS-1 trial (first Phase 3 trial of pamrevlumab in 356 IPF patients) is completed. While the company continues to enroll patients in ZEPHYRUS-2, the second Phase III trial of pamrevlumab in approximately 340 IPF patients.

Other than IPF, FibroGen is also evaluating pamrevlumab in Phase III clinical development for the treatment of Duchenne muscular dystrophy (DMD), and locally advanced unresectable pancreatic cancer (LAPC). Furthermore, as stated by the company, the drug demonstrated the potential for stabilization of disease and reversal of lung fibrosis in some patients.

As per the latest reports by FibroGen, topline data from the ZEPHYRUS-1 Phase III study of pamrevlumab in IPF is expected in mid-2023.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the pamrevlumab description, mechanism of action, dosage and administration, research and development activities in PF-ILD.
• Elaborated details on pamrevlumab regulatory milestones and other development activities have been provided in this report.
• The report also highlights the pamrevlumab research and development activities in PF-ILD across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around pamrevlumab.
• The report contains forecasted sales of for PF-ILD till 2032.
• Comprehensive coverage of the late-stage emerging therapies for PF-ILD.
• The report also features the SWOT analysis with analyst views for pamrevlumab in PF-ILD.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Pamrevlumab Analytical Perspective by DelveInsight

In-depth Pamrevlumab Market Assessment

This report provides a detailed market assessment of pamrevlumab for PF-ILD in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

Pamrevlumab Clinical Assessment

The report provides the clinical trials information of pamrevlumab for PF-ILD covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

• In the coming years, the market scenario for PF-ILD is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence pamrevlumab dominance.
• Other emerging products for PF-ILD are expected to give tough market competition to pamrevlumab and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of pamrevlumab in PF-ILD.
• Our in-depth analysis of the forecasted sales data of pamrevlumab from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the pamrevlumab in PF-ILD.

Key Questions

• What is the product type, route of administration and mechanism of action of pamrevlumab?
• What is the clinical trial status of the study related to pamrevlumab in PF-ILD and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the pamrevlumab development?
• What are the key designations that have been granted to pamrevlumab for PF-ILD?
• What is the forecasted market scenario of pamrevlumab for PF-ILD?
• What are the forecasted sales of pamrevlumab in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
• What are the other emerging products available and how are these giving competition to pamrevlumab for PF-ILD?
• Which are the late-stage emerging therapies under development for the treatment of PF-ILD?